Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Step Closer to Predicting Cancer Patients’ Drug Toxicity

By Drug Discovery Trends Editor | January 23, 2015

Being able to predict that a patient will adversely react to a drug that’s meant to be treating them is a key aim of personalized medicine, and could help to improve the patient’s overall treatment.
 
Researchers at the University of Adelaide are now one step closer to accurately predicting which cancer patients will experience severe toxicity from chemotherapy.
 
In a pilot study involving 34 patients, researchers looked at specific genetic variations in the patients’ immune system, and compared that with information about the types of cancer each patient had.
 
The researchers then produced a model that was able to predict – with more than 87% accuracy – the risk of patients having severe toxicity to their chemotherapy treatments.
 
“This is the first time that immune genetic factors have been used to predict the risk of toxicity for patients.  While much more work still needs to be done to test and finalise this model, we’re very pleased with the results so far,” says Dr Janet Coller from the University’s School of Medical Sciences, who is lead author of the study, published in the journal Supportive Care in Cancer.
 
Dr Coller says there are two specific genetic variations in the immune system that appear to play a role: a cell-signalling protein known as Tumor necrosis factor alpha, and a protein called Toll-like receptor 2.
 
“At this stage we’re not entirely sure how these genetic variants lead to increases in a person’s toxicity to chemotherapy, and it warrants further investigation,” Dr Coller says.
 
“But we have a strong indication that genetic variation is playing a role, and it is something that we could potentially test for in the future.  We’re excited about the results because at the moment there is no way of telling a patient how likely they are to experience toxicity from chemotherapy drugs. 
 
“Knowing this information will be vital in understanding whether or not certain patient groups need additional therapeutic support to help minimise severe toxic reactions,” she says. 
 
Source: University of Adelaide
 

Filed Under: Drug Discovery

 

Related Articles Read More >

Tiffany Hurd
CB Therapeutics biz dev lead sees upside for psychedelics in mental health and beyond
Pharmacovigilance
A new era of pharmacovigilance: Worldwide master key for drug safety monitoring
Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50